Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases in the United States. Its main pipeline targets chronic hepatitis B and includes Imdusiran, a GalNAc-conjugated, subcutaneously delivered RNAi candidate that is being studied in Phase 1 and Phase 2a trials, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b testing. The company says these programs are designed to suppress HBV antigens and help restore HBV-specific immune response. Arbutus also has a licensing agreement with Alnylam Pharmaceuticals related to LNP delivery technology. Founded in 2005 and formerly known as Tekmira Pharmaceuticals Corporation, the company adopted its current name in July 2015 and is headquartered in Warminster, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ABUS
|
$4.51
|
0.4% Upside
|
Fair
|
$5.18
|
15.1% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
5.5x
|
3.4x
|
4.6x
|
871.1 M
|
790.5 M
|
0.4%
|
61.4%
|
28.4
|
—
|
-21.4%
|
